NCT01366521View on ClinicalTrials.gov

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Asthma
Interventions
BIOLOGICAL

Mepolizumab

Monoclonal antibody

Trial Locations (11)

13619

GSK Investigational Site, Tallinn

13915

GSK Investigational Site, Marseille

14050

GSK Investigational Site, Berlin

15213

GSK Investigational Site, Pittsburgh

27103

GSK Investigational Site, Winston-Salem

33604

GSK Investigational Site, Pessac

34295

GSK Investigational Site, Montpellier

39112

GSK Investigational Site, Magdeburg

51014

GSK Investigational Site, Tartu

60596

GSK Investigational Site, Frankfurt am Main

82131

GSK Investigational Site, Gauting

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01366521 - Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils | Biotech Hunter | Biotech Hunter